Skip to main content
Premium Trial:

Request an Annual Quote

DermTech, Dermpath Ink Marketing Partnership

NEW YORK (GenomeWeb) – DermTech, a private developer of gene expression-based tests for skin diseases, announced today that it has formed a sales and marketing collaboration with Dermpath Diagnostics.

Under the terms of the deal, Dermpath — a Quest Diagnostics-owned dermatopathology services provider — will provide specialty dermatology representatives in up to 10 regional territories across the US to help DermTech in marketing its Pigmented Lesion assay (PLA), which analyzes the expression of two oncogenes to differentiate malignant melanoma from benign pigmented skin lesions.

Additional terms of the arrangement were not disclosed.

"This collaboration will significantly expand our ability to offer the PLA to dermatologists in the US," Sarah Dennison, vice president of marketing at DermTech, said in a statement. 

Michael Kramer, vice president of dermatopathology at Dermpath, added, "We are pleased to align with DermTech in offering their innovative PLA and to further our mission to provide comprehensive dermatopathology services to the medical community."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.